Semaglutide: What the Clinical Evidence Shows About This GLP-1 Agonist

What Is Semaglutide?

Semaglutide is a synthetic GLP-1 receptor agonist peptide with extensive Phase III clinical trial data — one of the few peptides in this space with an evidence base comparable to conventional pharmaceuticals, because it is one.

Semaglutide is a modified analog of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone produced by L-cells in the small intestine. It is the active ingredient in Ozempic (for type 2 diabetes), Wegovy (for chronic weight management), and Rybelsus (oral formulation for type 2 diabetes), all manufactured by Novo Nordisk.

Semaglutide is an outlier among the peptides covered on this site. While most peptides discussed here rely on preclinical data or limited clinical trials, semaglutide has been evaluated in multiple Phase III programs (SUSTAIN, STEP, SELECT) involving tens of thousands of participants. It is FDA-approved for two distinct indications and has demonstrated cardiovascular benefit in a large outcomes trial.

It was FDA-approved for type 2 diabetes (as Ozempic) in 2017 and for chronic weight management (as Wegovy) in 2021. For context on the broader class of GLP-1 medications, see our GLP-1 peptides guide.

Who this page is for, and who it isn’t for

This page is for people who want to understand what semaglutide does, what the clinical evidence supports, and what the known limitations and risks are. It is written for researchers, clinicians, patients evaluating their options, and informed readers.

This page is not a substitute for consultation with a prescribing physician. Semaglutide is a prescription medication with real risks and contraindications. It is not a casual supplement.

How Semaglutide Works

Semaglutide mimics a natural gut hormone (GLP-1) but with structural modifications that extend its half-life from minutes to about a week, enabling once-weekly dosing.

Structural modifications

Native GLP-1 has a half-life of approximately 2 minutes, too short for therapeutic use. Semaglutide addresses this through three key modifications:

• A C-18 fatty acid chain that promotes albumin binding, slowing renal clearance
• An amino acid substitution at position 8 that resists DPP-4 enzyme degradation
• An alpha-aminoisobutyric acid substitution that provides further enzymatic protection

The result is a half-life of approximately 7 days, enabling once-weekly dosing.

How it produces weight loss

Semaglutide’s weight loss effects operate through multiple concurrent pathways:

Central appetite suppression. GLP-1 receptors are expressed in the hypothalamus and brainstem, regions that regulate hunger and satiety. Semaglutide crosses the blood-brain barrier and activates these receptors, reducing hunger signals. Functional MRI studies show altered brain responses to food cues, with reduced activity in reward-related regions (Blundell et al., 2017).

Delayed gastric emptying. Semaglutide slows the rate at which food leaves the stomach, prolonging feelings of fullness after meals. This effect is most pronounced in early treatment and partially attenuates over time.

Altered food reward. Beyond simple appetite reduction, participants consistently report reduced food cravings and lower desire for high-fat, high-sugar foods. This aligns with GLP-1 receptor expression in mesolimbic dopamine pathways, the brain’s reward circuitry.

Glucose regulation. As a diabetes medication, semaglutide enhances glucose-dependent insulin secretion and suppresses inappropriate glucagon release. This improves glycemic control and contributes to metabolic improvements beyond weight loss.

Cardiovascular mechanism

The SELECT trial demonstrated that semaglutide reduces major adverse cardiovascular events independently of glucose lowering. The mechanism is not fully elucidated but may involve direct anti-inflammatory effects, reduced arterial plaque inflammation, and metabolic improvements associated with weight loss and improved insulin sensitivity.

What the Clinical Evidence Shows

Semaglutide has one of the most comprehensive evidence bases of any weight management intervention. The following summarizes key findings from its major trial programs.

The STEP trials (obesity)

The Semaglutide Treatment Effect in People with Obesity (STEP) program is a series of Phase III randomized controlled trials:

STEP 1 (n=1,961): Semaglutide 2.4 mg/week vs. placebo in adults with overweight/obesity without diabetes. Mean weight loss: 14.9% (semaglutide) vs. 2.4% (placebo) over 68 weeks. Approximately one-third of participants lost more than 20% of their body weight (Wilding et al., 2021).

STEP 2 (n=1,210): Adults with type 2 diabetes and overweight/obesity. Mean weight loss: 9.6% vs. 3.4% (placebo). The lower magnitude reflects the generally more resistant weight loss pattern in type 2 diabetes populations.

STEP 3 (n=611): Semaglutide combined with intensive behavioral therapy. Mean weight loss: 16.0% vs. 5.7%, demonstrating additive effects with lifestyle intervention.

STEP 5 (n=304): Extended treatment over 104 weeks (2 years). Mean weight loss maintained at 15.2%, demonstrating durability with continued use. However, STEP 1 extension data showed significant weight regain after discontinuation. Approximately two-thirds of lost weight was regained within one year of stopping.

The SUSTAIN trials (diabetes)

The SUSTAIN program established semaglutide’s efficacy for type 2 diabetes. Consistent HbA1c reductions of 1.5–1.8% were observed across trials. SUSTAIN-6 demonstrated cardiovascular safety with a 26% reduction in major adverse cardiovascular events (Marso et al., 2016).

The SELECT trial (cardiovascular outcomes)

SELECT (n=17,604) is the landmark cardiovascular outcomes trial. In obese/overweight adults without diabetes, semaglutide 2.4 mg/week reduced the composite major adverse cardiovascular events (MACE) endpoint by 20% over a median 39.8-month follow-up (Lincoff et al., 2023).

This trial fundamentally changed the clinical positioning of GLP-1 agonists — from “diabetes drugs with weight loss” to “cardiometabolic agents with broad benefit.” It is one of the most important clinical trial results in this therapeutic area in the past decade.

Body composition: the lean mass question

An important nuance: weight loss with semaglutide includes both fat mass and lean mass. DEXA scan data from clinical trials suggests approximately 60-70% of weight lost is fat mass and 30-40% is lean mass.

This ratio is similar to other caloric restriction approaches, but it is a real concern, particularly for older adults or anyone concerned about preserving muscle. Resistance training and adequate protein intake (>1.2 g/kg/day, ideally higher) appear to mitigate lean mass loss, though dedicated trials are limited.

For comparison, tirzepatide (a dual GIP/GLP-1 agonist) may have a somewhat more favorable body composition profile, though head-to-head data on this specific question is limited. See our GLP-1 guide for more on how these medications compare.

What Semaglutide Has Been Demonstrated to Do (Summary)

Based on Phase III clinical trial evidence:

• Weight loss: average 15% body weight reduction at the 2.4 mg dose over 68 weeks
• Appetite suppression: reduced hunger, fewer cravings, earlier satiety
• Glycemic control: HbA1c reduction of 1.5–1.8% in type 2 diabetes
• Cardiovascular protection: 20% reduction in MACE events (SELECT trial)
• Blood pressure reduction: modest systolic BP lowering
• Lipid improvement: reductions in triglycerides and LDL
• Liver fat reduction: potential benefit for NAFLD/NASH (studies ongoing)

Areas of active investigation include potential neuroprotective effects (the EVOKE Alzheimer’s disease program) and applications in other metabolic and inflammatory conditions.

Dosing

FDA-approved titration schedule (Wegovy, for obesity)

Semaglutide follows a mandatory dose titration to minimize gastrointestinal side effects:

• Weeks 1–4: 0.25 mg/week
• Weeks 5–8: 0.5 mg/week
• Weeks 9–12: 1.0 mg/week
• Weeks 13–16: 1.7 mg/week
• Week 17 onward: 2.4 mg/week

The titration is important. Skipping dose escalation steps commonly causes severe nausea and vomiting. The GI tract requires time to adapt.

FDA-approved dosing (Ozempic, for type 2 diabetes)

• Start: 0.25 mg/week for 4 weeks
• Step up: 0.5 mg/week for 4+ weeks
• Maximum: 1.0 mg/week (or 2.0 mg/week in newer protocols)

Compounded semaglutide

Compounding pharmacies produce semaglutide, often at lower cost than branded products. The FDA’s position on compounded semaglutide has been contentious, with Novo Nordisk challenging compounding and pharmacies arguing they fill access gaps during supply shortages.

Key considerations: purity verification through third-party testing (HPLC/MS) is important; concentrations vary by pharmacy; some compounders use semaglutide sodium vs. semaglutide base, which may affect dosing calculations; and reconstituted vials should be refrigerated.

Administration

• Injection: subcutaneous, once weekly, at any convenient site (abdomen, thigh, upper arm)
• Oral (Rybelsus): taken fasting with no more than 4 oz water, 30 minutes before any food or other medications
• Consistency matters: same day each week for injectable formulations

Side Effects and Safety

Common side effects

Gastrointestinal effects are the primary limitation and the reason for mandatory dose titration (see also our peptide safety guide for broader context):

• Nausea: 40-45% in clinical trials; typically worst during dose escalation; improves with time
• Vomiting: approximately 25%
• Diarrhea: 15-30%
• Constipation: 10-25%
• Abdominal pain: 10-20%
• Injection site reactions: mild, infrequent

Most GI effects are dose-dependent and improve over weeks. Slow titration and dietary modifications (smaller meals, avoiding fatty foods) help with management.

Serious adverse events

Pancreatitis. Rare but reported. Patients should be monitored for symptoms (severe abdominal pain radiating to the back). Semaglutide should be discontinued if pancreatitis is suspected.

Gallbladder disease. Increased risk of gallstones and cholecystitis during rapid weight loss. Risk is approximately 2–3x baseline, consistent with the general association between rapid weight loss and gallstone formation.

Thyroid C-cell tumors. Semaglutide carries a black box warning based on thyroid C-cell tumor findings in rodent studies. The human relevance is debated (the incidence in human clinical trials was not elevated) but it remains a theoretical concern. Semaglutide is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2.

Retinopathy complications. Observed in SUSTAIN-6, particularly in patients with pre-existing diabetic retinopathy and rapid glucose improvement. This is likely related to the speed of glycemic correction rather than a direct drug effect.

The lean mass question (revisited)

The loss of lean body mass (~30-40% of total weight lost) is a practical concern. Strategies commonly discussed to mitigate this include resistance training (minimum 2–3 times per week), high protein intake (1.2–1.6 g/kg ideal body weight per day), creatine supplementation, and body composition monitoring via DEXA when available.

Weight regain after discontinuation

STEP 1 extension data showed that participants regained approximately two-thirds of lost weight within one year of stopping semaglutide. This is not unique to semaglutide. It reflects the biological defense of body weight that makes sustained weight loss difficult through any approach. It does mean that for many people, semaglutide may require chronic use to maintain benefit, a consideration for long-term cost, side effect tolerance, and the (still limited) very-long-term safety data.

How Semaglutide Relates to Other Compounds

• Tirzepatide: a dual GIP/GLP-1 agonist that has shown even greater weight loss in clinical trials (up to ~20-22% in the SURMOUNT program). See our GLP-1 peptides guide for a direct comparison.
• AOD-9604: a peptide studied for fat loss through a different mechanism (GH fragment). The evidence base is much weaker than semaglutide’s. See our fat loss guide.
• Tesamorelin: an FDA-approved GHRH analog specifically demonstrated to reduce visceral fat. Different mechanism (GH-mediated) and different magnitude of effect than semaglutide.
• GH secretagogues like CJC-1295 and ipamorelin: sometimes discussed for body composition, but through GH/IGF-1 elevation rather than appetite/metabolic pathways. Evidence base is not comparable.

Legal Status

United States

FDA-approved prescription medication. Available as Ozempic (type 2 diabetes), Wegovy (obesity), and Rybelsus (oral, type 2 diabetes). Compounded semaglutide availability is subject to ongoing legal and regulatory proceedings. Research-grade semaglutide is also available through peptide suppliers.

International

Approved in the EU, UK, Canada, Australia, and many other markets for both diabetes and weight management.

Not a controlled substance

Semaglutide is a prescription medication but not a controlled substance. Obtaining it without a prescription is illegal, but it does not carry the same legal classification as scheduled drugs.

Frequently Asked Questions

How much weight can someone expect to lose on semaglutide?

The clinical trial average is approximately 15% of body weight at the 2.4 mg/week dose over 68 weeks. Individual results vary considerably. Some participants lost more than 20%, others less than 10%. Response depends on starting weight, dietary habits, physical activity, and individual biology.

Does the weight come back after stopping semaglutide?

Available data indicates most people regain significant weight after discontinuation. In the STEP 1 extension analysis, approximately two-thirds of lost weight was regained within one year. This reflects the body’s biological defense of its weight set point and is consistent with outcomes after other weight loss interventions. Transition strategies (lower maintenance doses, sustained lifestyle changes) may help, but long-term post-discontinuation data is limited.

Can semaglutide be used while trying to build or preserve muscle?

Yes, but it requires deliberate effort. Resistance training and high protein intake are important for minimizing lean mass loss. Some practitioners describe using lower semaglutide doses alongside resistance training programs, accepting slower fat loss in exchange for better body composition outcomes. Dedicated clinical trials on this approach are limited.

What is the difference between Ozempic, Wegovy, and compounded semaglutide?

Same active ingredient (semaglutide), different concentrations and approved indications. Ozempic is approved for type 2 diabetes (maximum dose 2.0 mg/week). Wegovy is approved for chronic weight management (target dose 2.4 mg/week). Compounded semaglutide is the same molecule produced by compounding pharmacies, typically at lower cost but with variable quality control.

Is semaglutide safe for long-term use?

Clinical data extends to 2 years (STEP 5) with sustained efficacy and tolerability. The SELECT trial (median 3.3 years) demonstrated cardiovascular benefit and acceptable safety. Truly long-term data (10+ years) does not yet exist. For a medication that many people may need to take chronically to maintain weight loss, this is a meaningful gap, though it is filling as post-marketing experience accumulates.

How does semaglutide compare to tirzepatide?

Tirzepatide has shown greater weight loss than semaglutide in clinical trials (approximately 20-22% vs. 15% body weight). Tirzepatide is a dual GIP/GLP-1 agonist, targeting an additional receptor. Both have strong evidence bases. See our GLP-1 guide for a detailed comparison.

References

1. Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” N Engl J Med. 2021;384(11):989-1002. PubMed
2. Marso SP, et al. “Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.” N Engl J Med. 2016;375(19):1834-1844. PubMed
3. Lincoff AM, et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.” N Engl J Med. 2023;389(24):2221-2232. PubMed
4. Blundell J, et al. “Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.” Diabetes Obes Metab. 2017;19(9):1242-1251. PubMed
5. Davies M, et al. “Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2).” Lancet. 2021;397(10278):971-984. [research needed]
6. Rubino D, et al. “Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4).” JAMA. 2021;325(14):1414-1425. [research needed]
7. Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” N Engl J Med. 2022;387(4):327-340. [research needed]

Related Articles

Peptide

AOD-9604: Research, Mechanism, and What the Evidence Actually Shows

An evidence-first look at AOD-9604 — the GH fragment studied for fat loss. Clinical trial results, mechanism of action, safety data, and an honest assessment of efficacy.

Peptide

Tesamorelin: The FDA-Approved GHRH Analog With Clinical Evidence for Visceral Fat Reduction

An evidence-first review of tesamorelin (Egrifta) — the only currently FDA-approved GHRH analog. Phase III data on visceral fat reduction, emerging cognitive research, and off-label considerations.

Peptide

Tirzepatide: What the Clinical Evidence Shows About This Dual Incretin Agonist

An evidence-based review of tirzepatide (Mounjaro/Zepbound), covering clinical trial data on weight loss, diabetes, cardiovascular outcomes, and safety.